BMS-963272
Sponsors
Bristol-Myers Squibb
Conditions
HealthyHealthy ParticipantsNonalcoholic Fatty Liver DiseaseObese But Otherwise Healthy Participants
Phase 1
Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects
CompletedNCT02327273
Start: 2014-10-31End: 2015-05-31Updated: 2015-07-22
A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy Adults
CompletedNCT04116632
Start: 2019-09-30End: 2020-02-10Updated: 2020-05-15
A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin
CompletedNCT04124003
Start: 2019-10-08End: 2020-01-03Updated: 2020-03-10
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease
TerminatedNCT04766476
Start: 2021-02-24End: 2021-08-12Updated: 2022-06-09